All hypermutated samples were observed in recurrent glioblastoma after treatment with TMZ, with 94% acquiring the following mutations absent in matched newly diagnosed glioblastoma samples: MSH2 and MSH6 [79]. Here, MSH2 is linked to glioblastoma.